|
PSA Concentration by Serum Antibody Testing among PSA Eligible Men (Age 40–49), NHANES 2001 – 2004 |
|||||
| Variable |
n |
Predicted margin geometric mean PSA (ng/ml) |
p-value |
Predicted margin percent free PSA |
p-value |
|
|
|||||
| Serum test for herpes simplex virus-2 exposure |
737 |
||||
| Positive* |
176 |
0.70 (0.63 to 0.77) |
0.231 |
30.2 (28.1 to 32.4) |
0.228 |
| Negative or Indeterminate† |
561 |
0.74 (0.70 yo 0.79) |
Reference |
31.7 (30.4 to 33.0) |
Reference |
| Serum test for T. pallidum exposure |
737 |
||||
| Current‡ or remote§ infection |
27 |
0.84 (0.66 to 1.06) |
0.253 |
28.7 (22.7 to 34.7) |
0.398 |
| No infection¶ |
710 |
0.73 (0.69 to 0.78) |
Reference |
31.5 (30.3 to 32.7) |
Reference |
|
* Serum has antibodies to HSV-2 gP-2 protein † Three results were indeterminate ‡ positive or indeterminate • positive or indeterminate EIA test for T. pallidum antibodies, and rapid plasma reagin (RPR) ≥ 8 §positive EIA test, and 1 ≤ RPR ≤ 8 and a positive T. pallidum-particle agglutination (TP-PA) ¶ negative EIA test, or positive or indeterminate EIA test and RPR score 0–8 and negative TP-PA | |||||
Werny et al. Infectious Agents and Cancer 2007 2:19 doi:10.1186/1750-9378-2-19 |
|||||